3 completed, 2 recruiting, 1 terminated. 5 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 2, Terminated 1 |
| Phase 1 | 4 | Completed 2, Recruiting 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Xenothera SAS: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polyspecific Antibodies in Lymphoproliferative T-cell Disorders LIS1 - Peripheral T Cells Lymphoma (PTCL) | Phase 1 / Phase 2 | Recruiting | Xenothera SAS | 54 | 2024-07-09 | 2026-08-20 |
| FIH XON7 in Advanced/Metastatic Solid Tumors XON7 - Advanced Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Xenothera SAS | 255 | 2023-11-14 | 2026-08-20 |
| A First-in-Human Study With XAB05 in Healthy Subjects Experimental - Infection, Bacterial | Phase 1 | Completed | Xenothera SAS | 25 | 2022-01-24 | 2022-08-12 |
| Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19 XAV-19, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Xenothera SAS | 290 | 2021-04-28 | 2023-01-23 |
| Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia XAV-19, Placebo - SARS Virus | Phase 2 | Completed | Nantes University Hospital | 416 | 2020-09-01 | 2022-03-25 |
| First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients LIS1 - Kidney Transplant | Phase 1 / Phase 2 | Completed | Xenothera SAS | 10 | 2019-11-26 | 2022-08-17 |
COVID-19 (2) · Bacterial Infections (1) · Lymphoma, Follicular (1) · Neoplasm Metastasis (1) · Pneumonia (1) · Severe Acute Respiratory Syndrome (1)
XAV-19 (2)
France (3) · Belgium (1) · Bulgaria (1) · Czechia (1) · Greece (1) · Italy (1) · Martinique (1) · Netherlands (1) · Reunion (1) · Romania (1) · Spain (1) · Turkey (Türkiye) (1)
Benjamin Gaborit (1) · Dr Ondrej Viklicky (1) · Khadid Abd-Elaziz, MD (1)
PMID 33750432, PMID 34181475, PMID 34473343, PMID 36700518, PMID 38421879, PMID 38694503
2023 (2)